Atossa Therapeutics Inc.
Organization details
- Legal name
- Atossa Therapeutics Inc.
- Former names
- Atossa Genetics Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Seattle
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ATOS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001488039
- EIN
- 26-4753208
- Wikidata ID
- Q107517747
Board of directors
-
Gregory L. Weaver · Director · Former EVP, CFO, & DirectorSince 2023
-
H. Lawrence Remmel · DirectorSince 2023
-
Jonathan Finn · DirectorSince 2023
-
Richard I. Steinhart · DirectorSince 2023
-
Shu-Chih Chen · DirectorSince 2023
-
Stephen J. Galli · DirectorSince 2023
-
Steven C. Quay · Director · President & CEOSince 2023
-
Tessa Cigler · DirectorSince 2024
Chief executives
Director election results
Annual meeting of May 4, 2023. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
59.9%
-
83.5%
Board connections
1 of this board's directors also sit on 1 other board. 1 is in the same sector.
-
Actinium Pharmaceuticals Inc. (Delaware) Same sectorvia Richard I. Steinhart
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 12, 2026 | Richard I. Steinhart Director | Grant or award | +10,000 | — | — |
| May 12, 2026 | Shu-Chih Chen Director | Grant or award | +10,000 | — | — |
| May 12, 2026 | H. Lawrence Remmel Director | Grant or award | +10,000 | — | — |
| May 12, 2026 | Jonathan Finn Director | Grant or award | +10,000 | — | — |
| May 12, 2026 | Stephen J. Galli Director | Grant or award | +10,000 | — | — |
| May 12, 2026 | Tessa Cigler Director | Grant or award | +10,000 | — | — |
| Mar 27, 2026 | Steven C. Quay Director, Officer (President & CEO) | Grant or award | +65,000 | — | — |
| Mar 26, 2026 | Daniel Mark James Officer (Chief Financial Officer) | Grant or award | +63,000 | — | — |
| Jan 20, 2026 | Steven C. Quay Director, Officer (President & CEO) | Grant or award | +325,203 | — | — |
| May 21, 2025 | Steven C. Quay Director, Officer (President & CEO) | Open-market purchase | +11,239 | $0.88 | $9,890 |
| Mar 26, 2025 | H. Lawrence Remmel Director | Open-market purchase | +10,000 | $0.70 | $7,000 |
| Apr 10, 2024 | Jonathan Finn Director | Open-market purchase | +25,000 | $1.77 | $44,250 |
| Nov 15, 2023 | Gregory L. Weaver Director, Officer (Former EVP, CFO, & Director) | Open-market sale | −50,000 | $0.65 | $32,500 |
| Jun 20, 2023 | Gregory L. Weaver Director, Officer (EVP & CFO) | Open-market purchase | +50,000 | $0.97 | $48,500 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Atossa Therapeutics Inc.
Who is the CEO of Atossa Therapeutics Inc.?
Steven C. Quay is Atossa Therapeutics Inc.'s President & CEO.
How many directors are on Atossa Therapeutics Inc.'s board?
Atossa Therapeutics Inc.'s board has 8 directors: Gregory L. Weaver, H. Lawrence Remmel, Jonathan Finn, Richard I. Steinhart, Shu-Chih Chen, Stephen J. Galli, Steven C. Quay and Tessa Cigler.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="atossa-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.